Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.74 |
| ▸ | RPTOR | Q8N122 | 5/20 | 0.71 |
| ▸ | MLST8 | Q9BVC4 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413783 | 1.00 | MTOR (0.90) | MTORKCNH2PIK3CARPTORMLST8 | |
| SCHEMBL1831120 | 1.00 | MTOR (0.90) | MTORKCNH2PIK3CARPTORMLST8 | |
| SCHEMBL441257 | 0.95 | MTOR (1.00) | MTORKCNH2PIK3CARPTORMLST8 | |
| SCHEMBL441138 | 0.95 | MTOR (1.00) | MTORKCNH2PIK3CARPTORMLST8 | |
| SCHEMBL1831606 | 0.95 | MTOR (1.00) | MTORKCNH2PIK3CARPTORMLST8 | |
| SCHEMBL441316 | 0.94 | MTOR (0.90) | MTORKCNH2PIK3CARPTORMLST8 | |
| SCHEMBL441315 | 0.94 | MTOR (0.90) | MTORKCNH2PIK3CARPTORMLST8 | |
| SCHEMBL412938 | 0.93 | MTOR (0.78) | MTORKCNH2PIK3CARPTORMLST8 | |
| SCHEMBL442197 | 0.93 | MTOR (0.78) | MTORKCNH2PIK3CARPTORMLST8 | |
| SCHEMBL1830948 | 0.92 | MTOR (0.77) | MTORKCNH2PIK3CARPTORMLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318377-B1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2013-08-21 | — | — | EP | claimed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2406258-B1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LTD (GB) | 2014-12-03 | — | — | EP | disclosed |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED | 2014-10-02 | — | — | US | disclosed |
| US-8785457-B2 | Pyrimidine derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2014-07-22 | — | — | US | disclosed |
| EP-2318377-B1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2406258-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Cellzome Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| EP-2318377-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010103094-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | MTOR 1/4885KCNH2 4420/4885PIK3CA 29/4885 |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | MTOR 1/4885KCNH2 4420/4885PIK3CA 29/4885 |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | MTOR 1/4885KCNH2 4005/4885PIK3CA 4/4885 |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | MTOR 1/4885KCNH2 4005/4885PIK3CA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.